CKMT2 monoclonal antibodies are widely used in molecular and cellular biology. Validated applications and protocols include:
Prognostic Biomarker: Low CKMT2 expression correlates with better immunotherapy outcomes in five cancer types (e.g., lung adenocarcinoma) .
Tumor Microenvironment: CKMT2 interacts with immune-related genes (e.g., TLRs, TRAF6) and regulates oxidative stress pathways .
Reperfusion Injury: Plasma CKMT2 levels rise post-reperfused myocardial infarction (MI), linking it to mitochondrial damage and impaired cardiac function .
CKMT2 stabilizes mitochondrial membrane potential () and modulates ROS production, critical for immune cell function .
CKMT2 monoclonal antibodies are rigorously validated:
Therapeutic Potential: CKMT2 inhibition may enhance immunotherapy efficacy in cancers with low CKMT2 expression .
Biomarker Utility: Plasma CKMT2 could aid in diagnosing reperfusion injury post-MI .
Limitations: Limited data on CKMT2 isoform-specific roles and off-target effects in polyclonal preparations .